Skip to content
Study details
Enrolling now

Atezolizumab Plus Etoposide and Platinum for Bladder Cancer

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT IDNCT05312671ClinicalTrials.gov data as of Apr 2026
Phase

Phase 2

Target enrollment

63

Study length

about 7.4 years

Ages

18+

Locations

2 sites in DC, MD

What this study is about

This trial is testing a treatment with atezolizumab, platinum, and etoposide in people with bladder cancer. The goal is to see if the combination therapy leads to a pathologic complete response after cystectomy.

Simplified from trial records by PatientMatch.

What you may be asked to do

  • 1.Take Atezolizumab
  • 2.Take Carboplatin
  • 3.Take Cisplatin
  • +2 more

Participation Burden

What's physically and logistically required of participants.

Logistics & Travel
In-person visits

Requires travel to a study site

Physical Intervention
Injection / IVInjection / IV

How treatment is administered

Treatment Assignment
All receive treatment

Everyone gets the investigational treatment.

Extracted study details

Pulled from the trial record to show what is being tested and what the study is measuring.

Drug classes

atezolizumab, carboplatin, cisplatin (Platinum chemotherapy; crosslinks DNA to stop replication), etoposide

Drug routes

injection (Injection), injection, intravenous

Endpoints

Secondary: 1-year overall survival rate (1-yr OS), 2-year overall survival rate (2-yr OS), Disease Free Survival, Safety and tolerability of combination chemotherapy and cystectomy as assessed by number of participants experiencing adverse events

Body systems

Oncology